Lycia Therapeutics, Inc. (NASDAQ:LYCA) Stock Short Interest Report for October

Lycia Therapeutics, Inc. (NASDAQ:LYCA) saw a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 304,185 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average daily volume of 400,880 shares, the short-interest ratio is currently 0.8 days.

Insider Buying and Selling at Lycia Therapeutics

In other Lycia Therapeutics news, major shareholder Venrock Healthcare Capital Par bought 8,305 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were bought at an average cost of $26.95 per share, with a total value of $223,819.75. Following the completion of the purchase, the insider directly owned 6,858,542 shares of the company’s stock, valued at $184,837,706.90. This trade represents a 0.12% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have bought 2,078,749 shares of company stock worth $38,526,342 in the last ninety days.

Lycia Therapeutics Trading Down 5.0%

NASDAQ:LYCA traded down $1.63 during trading hours on Friday, hitting $31.20. The company had a trading volume of 189,539 shares, compared to its average volume of 471,117. Lycia Therapeutics has a 52 week low of $22.19 and a 52 week high of $36.49.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Lycia Therapeutics to a “hold” rating in a report on Saturday, October 31st.

About Lycia Therapeutics

Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.